Robert E Wolf
Overview
Explore the profile of Robert E Wolf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
809
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pace L, Ayanian J, Wolf R, Knowlton R, Gershman S, Hawkins S, et al.
Cancer Med
. 2022 Mar;
11(13):2679-2686.
PMID: 35312162
Background: Testing for BRCA1/2 pathogenic variants is recommended for women aged ≤45 years with breast cancer. Some studies have found racial/ethnic and socioeconomic disparities in testing. We linked Massachusetts' All-Payer...
2.
He Y, Wolf R, Normand S
Health Serv Outcomes Res Methodol
. 2021 May;
10(3-4):111-133.
PMID: 33981181
With health care reform passing in the United States, much effort is directed toward developing and disseminating comparative information on standardized processes of care for health care providers. We propose...
3.
Hill E, Wake M, Carapinha R, Normand S, Wolf R, Norris K, et al.
Ethn Dis
. 2016 Apr;
26(2):245-54.
PMID: 27103776
Background And Objective: Women of color (WOC) (African American, Hispanic, Native American/Alaskan Native, and Asian American) faculty remain disproportionately underrepresented among medical school faculty and especially at senior ranks compared...
4.
Yeh R, Mauri L, Wolf R, Romm I, Lovett A, Shahian D, et al.
JAMA Intern Med
. 2015 Jan;
175(3):454-6.
PMID: 25559059
No abstract available.
5.
Alameddine A, Visintainer P, Normand S, Wolf R, Alameddine Y
Am J Clin Oncol
. 2014 Sep;
40(2):122-124.
PMID: 25198111
Background: The postprocedural state after cardiac revascularization interventions is characterized by intense inflammation and activation of inflammatory cytokines due to myonecrosis and ischemia/reperfusion injury. Involvement of similar processes also participates...
6.
Stamou S, Robich M, Wolf R, Lovett A, Normand S, Sellke F
J Thorac Cardiovasc Surg
. 2011 Dec;
144(2):486-92.
PMID: 22154790
Objective: To evaluate the clinical outcomes after aortic valve replacement or aortic valve replacement and coronary artery bypass grafting in a large contemporary population, and to determine if outcomes are...
7.
Yeh R, Normand S, Wolf R, Jones P, Ho K, Cohen D, et al.
Circulation
. 2011 Sep;
124(14):1557-64.
PMID: 21900079
Background: Drug-eluting stents (DES) for percutaneous coronary intervention decrease the risk of restenosis compared with bare metal stents. However, they are costlier, require prolonged dual antiplatelet therapy, and provide the...
8.
Shahian D, Wolf R, Iezzoni L, Kirle L, Normand S
N Engl J Med
. 2010 Dec;
363(26):2530-9.
PMID: 21175315
Background: Several countries use hospital-wide mortality rates to evaluate the quality of hospital care, although the usefulness of this metric has been questioned. Massachusetts policymakers recently requested an assessment of...
9.
Garg P, Normand S, Silbaugh T, Wolf R, Zelevinsky K, Lovett A, et al.
Circulation
. 2008 Nov;
118(22):2277-85, 7p following 2285.
PMID: 19001019
Background: Patients with diabetes mellitus (DM) are at high risk for restenosis, myocardial infarction, and cardiac mortality after coronary stenting, and the long-term safety of drug-eluting stents (DES) relative to...
10.
Mauri L, Silbaugh T, Wolf R, Zelevinsky K, Lovett A, Zhou Z, et al.
Circulation
. 2008 Oct;
118(18):1817-27.
PMID: 18852368
Background: Drug-eluting stents (DES) reduce the need for repeat revascularization, but their long-term safety relative to that of bare-metal stents (BMS) in general use remains uncertain. We sought to compare...